US3873433A - Method of demonstrating normal and pathological plasm-lipoprotein patterns in human body liquids - Google Patents

Method of demonstrating normal and pathological plasm-lipoprotein patterns in human body liquids Download PDF

Info

Publication number
US3873433A
US3873433A US426202A US42620273A US3873433A US 3873433 A US3873433 A US 3873433A US 426202 A US426202 A US 426202A US 42620273 A US42620273 A US 42620273A US 3873433 A US3873433 A US 3873433A
Authority
US
United States
Prior art keywords
developing solution
lipoprotein
carrier
demonstrating
heparin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US426202A
Inventor
Dietrich Seidel
Heinrich Wieland
Johann Eibl
Gerald Eder
Ewald Molinari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oesterreichisches Institut fuer Haemoderivate
Original Assignee
Immuno AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno AG filed Critical Immuno AG
Application granted granted Critical
Publication of US3873433A publication Critical patent/US3873433A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G01N27/44704—Details; Accessories
    • G01N27/44717—Arrangements for investigating the separated zones, e.g. localising zones
    • G01N27/44721—Arrangements for investigating the separated zones, e.g. localising zones by optical means
    • G01N27/44726—Arrangements for investigating the separated zones, e.g. localising zones by optical means using specific dyes, markers or binding molecules

Definitions

  • the invention relates to a method of demonstrating normal and pathological plasm-liporprotein patterns in human body liquids by electrophoretical separation of the lipoproteins in a carrier medium, such as a gel, or on foils, and an apparatus for carrying out the method.
  • the analysis of the serum-plasm-lipoproteins is a prerequisite for an exact diagnosis of different forms of hyperlipoproteinernia and demands have been raised in the past for finding a reliable, easily practicable technique of identifying the normal and abnormal lipoprotein fractions.
  • Demonstration methods are known that are based on the electrophoresis of human body liquids.
  • the lipoproteins of human. serum or the like are subjected to the influence of an electric field in a solid migration medium, mainly a gel, the migration of the lipoproteins causing a separation effect.
  • the lipoprotein bands are made visible in the known method by coloring with lipid coloring agents or by immunological precipitations, e.g. with antiserum.
  • an ultracentrifugation is necessary; the known methods have the disadvantage that they require such a high expenditure of work and such costly apparatus that a complete lipoprotein analysis can be carried out in special laboratories only.
  • the method of the invention which starts from the electrophoretical separation of the lipoproteins in a carrier medium, such as a gel, or on foils, is characterised in that after the required electrophoretical separa tion effect has occurred, the carrier medium is treated with a developing liquid, which comprises one or several of the following substances: polyanions, such as heparin or dextran sulfate, sodium-dodecylsulfate (SOS), sodium-phosphotungstic acid, sodium oleate, sodium salts ofbile acids, suitably in the presence of bivalent cations, such as magnesium and calcium, wherein complex salts of low solubility are formed with the lipoproteins.
  • a developing liquid which comprises one or several of the following substances: polyanions, such as heparin or dextran sulfate, sodium-dodecylsulfate (SOS), sodium-phosphotungstic acid, sodium oleate, sodium salts ofbile acids, suitably in the presence of bivalent
  • the chemical composition of the developing solution or the kind of polyanions to be used, respectively, depends upon the lipoproteins that are to be demonstrated.
  • a developer containing heparin, magnesium ions and sodium chloride, is used.
  • a carrier e.g. a gel plate, is used for demonstrating the LP-X-lipoprotein, the carrier already containing the developing solution or parts of it.
  • the carrier is treated in turns with different developing solutions, the one containing heparin and magnesium ions and the other dextran sulfate and calcium ions.
  • the invention comprises an apparatus for carrying out the method of the invention, which, in a manner known, possesses a carrier in form of a plate bearing a layer of the migration medium, e.g. of the gel, said carrier being immersed into an electrolyte or in a buffer solution.
  • a carrier in form of a plate bearing a layer of the migration medium, e.g. of the gel, said carrier being immersed into an electrolyte or in a buffer solution.
  • the apparatus of the invention comprises a row of slits or holes and possibly a device for bringing into touch the plate-formed carrier with the developing solution.
  • the row of holes or slits is suitably arranged on the side of the anode and for demonstrating the lipoprotein pattern VLDL, LDL, HDL and type III, the row is arranged on the side of the cathode.
  • the row of holes may however also be arranged in the center of the gel carrier having the form of a plate, in which case starting from this row, the lipoprotein LP-X migrates in the direction towards the cathode and the other lipoproteins in the direction towards the anode.
  • the carrier having the form of a plate, is U-shaped and insertable into an electrolyte or into a buffer solution receiving container, respectively, which is divided in longitudinal direction by a separating dam into an anode region and a cathode region.
  • the drawing shows the apparatus of the invention by way of an example.
  • FIG. 1 illustrates a vertical section of the apparatus and FIG. 2 is a top view of the gel carrier.
  • FIG. 3 shows representations of plasm lipoprotein patterns received arrording to the invention.
  • the apparatus comprises a rectangular vessel 1 which may be covered by a lid 2.
  • Platinum sheets 3 and 4 or platinum wires, respectively, serve as cathode K and anode A which continue in the interior of the vessel along the side walls and along part of the bottom.
  • Fillets 5 extend in upward direction from the bottom of the vessel; they represent a separating dam and divide the vessel 1 in longitudinal direction into the cathode and the anode region.
  • the gel plate 7 rests on the fillets 5, thus bridging the separating dam and immerses into the buffer solution with its limbs 8 extending downwardly.
  • the gel plate is cast into an about U-shaped stencil 9.
  • the stencil is suitably made of plastics.
  • a row of slits 10 which serves for receiving the human body liquid to be examined, e.g. the human serum.
  • the lipoproteins migrate in the direction of the anode and are thereby separated into the individual fractions depending upon their migration speed.
  • the stencil is removed from the apparatus and is immersed into a container (not shown) which holds the developing solution. It is however also possible to drop or spray the developing solution onto the stencil, thus making the individual lipoprotein bands visible after an appropriate period of influence.
  • EXAMPLE 1 For demonstrating the lipoprotein bands in the human serum, the electrophoresis was carried out in an agarose migration medium as described by R. I. Noble, I. Lipid Res. 9.693 (1968). A veronal buffer with a pH of 8.6 and with an ionic strength of 0.05 was used. After the electrophoresis had continued for an hour, the stencil was removed from the apparatus and put into a developing bath which consisted of 0.55 dextran-sulfate 2,000 and of a 2.2 aqueous calciumchloride solution. The carrier was allowed to stay in the bath for 15 to 20 minutes at room temperature. During that period a complete precipitation of the following lipoprotein bands occurred:
  • chylomicrons B-lipoproteins pre-[i-lipoproteins OZ-llPOPI'OIGlHS, which in FIG. 3a are denominated in turn with 1,2,3 and 4.
  • EXAMPLE 2 In accordance with example 1, type III human serum on an agar stencil was subjected to the electrophoresis in a veronal buffer having a pH of 8.6 and an ionic strength of 0.05 for the purpose of determining the hyperlipoproteinemia. After the electrophoresis had continued for an hour, the stencil was removed and put into a developing bath consisting of 0.25 heparin and 0.95 70 magnesium chloride in a 0.95 aqueous sodium-chloride solution and was allowed to stay in the bath for 20 minutes. The precipitation for the field VLDL, characteristic of type III was clearly to be recognised and is denominated with 5 in FIG. 3b. The field extends from the B-position 2 as far as the pre-B- position 3.
  • EXAMPLE 3 For demonstrating LPX-lipoprotein, four samples of human serum were inserted into the four holes of an object holder carrying an agar plate and by means of filter paper the object holder was connected with a veronal buffer solution, having a pH of 8.6 and an ionic strength of 0.05. The samples thus prepared were subjected to the electrophoresis. After the electrophoresis had continued for half an hour, the object holder was removed and put into a developing bath consisting of 0.25 heparin and 0.95 magnesium chloride in 0.9 aqueous sodium-chloride solution, and was allowed to stay in the bath for minutes. Two samples which are denoted with N in FIG. 3c were negative, in the other two positive samples, denoted with P, the LPX- band was easily recognisable and was denoted with 6.
  • EXAMPLE Human full plasm was subjected to a polyacrylamide-electrophoresis, according to the method by B. J. Davis, Ann. N.Y. Acad. Sci. 121, 404 (1964), wherein a tris-glycin buffer [tris-(hydroxymethyl)- aminomethane-buffer] with a pH of 8.8 and an acrylamide-monomer concentration of 3.5/7 was used.
  • a tris-glycin buffer [tris-(hydroxymethyl)- aminomethane-buffer] with a pH of 8.8 and an acrylamide-monomer concentration of 3.5/7 was used.
  • the glass tube was removed from the apparatus, the polyacryl-amide gel was removed and treated with a developing solution of the following composition: 0.55 dextran sulfate 2,000 and 2.2 aqueous calcium-chloride solution.
  • pre-B-lipoproteins B-lipoproteins a-lipoproteins which are denoted with 3,2 and 4 in FIG. 3d.
  • a method of demonstrating normal and pathological plasm-lipoprotein patterns in human body liquids which comprises electrophoretically separating lipoproteins in a carrier medium or on foils,
  • a developing solution comprising at least one of the following substances: polyanions, selected from the group consisting of heparin and dextran sulfate, sodiumdodcyl -sulfate (SOS), sodium phosphotung stic acid, sodium oleate, sodium salts of bile acids, lowsoluble complex salts being formed with the lipo- 1 proteins.
  • polyanions selected from the group consisting of heparin and dextran sulfate, sodiumdodcyl -sulfate (SOS), sodium phosphotung stic acid, sodium oleate, sodium salts of bile acids, lowsoluble complex salts being formed with the lipo- 1 proteins.
  • bivalent cations selected from the group consisting of magnesium and calcium, are additionally present in the developing solution.
  • a method according toclaim 1 wherein for selectively demonstrating lipoprotein type III and lipoproteins VLDL, LDL and HDL the carrier is successively treated with a first developing solution and a second developing solution, the first developing solution comprising heparin and magnesium ions and the second developing solution comprising dextran sulfate and calcium ions.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Electrochemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A method for the demonstration of normal and pathological plasmlipoprotein patterns in human body liquids by electrophoretical separation of the lipoproteins in a carrier medium, such as a gel, or on foils, which consists in that after the desired electrophoretical separation effect has been achieved the carrier is treated with a developing solution comprising polyanions, and an apparatus for carrying out the method.

Description

States atent' 1 Seidel et a1.
[ 1 Mar. 25, 1975 [58] Field of Search 204/180 0, 299
[56] References Cited UNITED STATES PATENTS 3,766,047 10/1973 Elevitch 204/299 3,773,647 11/1973 Mandle et a1 204/299 3,783,118 l/1974 Hjerten v. 204/180 G Primary Examiner-John H. Mack Assistant Examiner-A. C. Prescott Attorney, Agent, or Firm-Steinberg & Blake 10 Claims, 6 Drawing Figures METHOD OF DEMONSTRATING NORMAL AND PATHOLOGICAL PLASM-LIPOPROTEIN PATTERNS IN HUMAN BODY LIQUIDS [75] Inventors: Dietrich Seidel; Heinrich Wieland,
both of Heidelberg, Germany; Johann Eibl, Vienna, Austria; Gerald' Eder, Vienna, Austria; Ewald Molinari, Vienna, Austria [73] Assignee: l mmuno Aktiengesellschaft Fur Chemisch medizinische, Vienna, Austria [22] Filed: Dec. 19, 1973 [21] Appl. No.: 426,202
[30] Foreign Application Priority Data Feb. 12, 1973 Austria 1218/73 [52] US. Cl. 204/180 G, 204/180 S, 204/299 [51] Int. Cl. B0lk 5/00 l i :8 f X 5 =1 PATENIEDmzsms 3 73 4:33
sum 1 p g METHOD OF DEMONSTRATING NORMAL AND PATHOLOGICAL PLASM-LIPOPROTEIN PATTERNS IN HUMAN BODY LIQUIDS The invention relates to a method of demonstrating normal and pathological plasm-liporprotein patterns in human body liquids by electrophoretical separation of the lipoproteins in a carrier medium, such as a gel, or on foils, and an apparatus for carrying out the method.
The analysis of the serum-plasm-lipoproteins is a prerequisite for an exact diagnosis of different forms of hyperlipoproteinernia and demands have been raised in the past for finding a reliable, easily practicable technique of identifying the normal and abnormal lipoprotein fractions. Demonstration methods are known that are based on the electrophoresis of human body liquids. Therein the lipoproteins of human. serum or the like are subjected to the influence of an electric field in a solid migration medium, mainly a gel, the migration of the lipoproteins causing a separation effect. The lipoprotein bands are made visible in the known method by coloring with lipid coloring agents or by immunological precipitations, e.g. with antiserum. In many cases, in combination with it, an ultracentrifugation is necessary; the known methods have the disadvantage that they require such a high expenditure of work and such costly apparatus that a complete lipoprotein analysis can be carried out in special laboratories only.
It is the object of this invention to provide a method which overcomes these disadvantages, which is practicable in any laboratory and guarantees reliable results.
The method of the invention, which starts from the electrophoretical separation of the lipoproteins in a carrier medium, such as a gel, or on foils, is characterised in that after the required electrophoretical separa tion effect has occurred, the carrier medium is treated with a developing liquid, which comprises one or several of the following substances: polyanions, such as heparin or dextran sulfate, sodium-dodecylsulfate (SOS), sodium-phosphotungstic acid, sodium oleate, sodium salts ofbile acids, suitably in the presence of bivalent cations, such as magnesium and calcium, wherein complex salts of low solubility are formed with the lipoproteins.
The chemical composition of the developing solution or the kind of polyanions to be used, respectively, depends upon the lipoproteins that are to be demonstrated.
For demonstrating the abnormal LP-X-lipoprotein suitably a developer, containing heparin, magnesium ions and sodium chloride, is used.
For demonstrating the abnormal lipoprotein type III, it is also suitable to use a developer containing heparin, magnesium ions and sodium chloride.
According to a modified embodiment of the invention, a carrier, e.g. a gel plate, is used for demonstrating the LP-X-lipoprotein, the carrier already containing the developing solution or parts of it.
If the lipoprotein type III, on the one hand, and the lipoproteins VLDL, LDL and HDL, on the other hand, are to be demonstrated selectively, the carrier is treated in turns with different developing solutions, the one containing heparin and magnesium ions and the other dextran sulfate and calcium ions.
Furthermore, the invention comprises an apparatus for carrying out the method of the invention, which, in a manner known, possesses a carrier in form of a plate bearing a layer of the migration medium, e.g. of the gel, said carrier being immersed into an electrolyte or in a buffer solution.
The apparatus of the invention comprises a row of slits or holes and possibly a device for bringing into touch the plate-formed carrier with the developing solution. 1
For demonstrating the LP-X-lipoprotein the row of holes or slits is suitably arranged on the side of the anode and for demonstrating the lipoprotein pattern VLDL, LDL, HDL and type III, the row is arranged on the side of the cathode.
The row of holes may however also be arranged in the center of the gel carrier having the form of a plate, in which case starting from this row, the lipoprotein LP-X migrates in the direction towards the cathode and the other lipoproteins in the direction towards the anode.
According to a preferred embodiment, the carrier, having the form of a plate, is U-shaped and insertable into an electrolyte or into a buffer solution receiving container, respectively, which is divided in longitudinal direction by a separating dam into an anode region and a cathode region.
The drawing shows the apparatus of the invention by way of an example.
FIG. 1 illustrates a vertical section of the apparatus and FIG. 2 is a top view of the gel carrier.
FIG. 3 (FIGS. 30 3d) shows representations of plasm lipoprotein patterns received arrording to the invention.
The apparatus comprises a rectangular vessel 1 which may be covered by a lid 2. Platinum sheets 3 and 4 or platinum wires, respectively, serve as cathode K and anode A which continue in the interior of the vessel along the side walls and along part of the bottom. Fillets 5 extend in upward direction from the bottom of the vessel; they represent a separating dam and divide the vessel 1 in longitudinal direction into the cathode and the anode region. The gel plate 7 rests on the fillets 5, thus bridging the separating dam and immerses into the buffer solution with its limbs 8 extending downwardly. The gel plate is cast into an about U-shaped stencil 9. The stencil is suitably made of plastics. In the gel plate on the side of the cathode a row of slits 10 is provided, which serves for receiving the human body liquid to be examined, e.g. the human serum. By applying an electric field, the lipoproteins migrate in the direction of the anode and are thereby separated into the individual fractions depending upon their migration speed. As soon as the required separation effect has been achieved, the stencil is removed from the apparatus and is immersed into a container (not shown) which holds the developing solution. It is however also possible to drop or spray the developing solution onto the stencil, thus making the individual lipoprotein bands visible after an appropriate period of influence.
EXAMPLE 1 For demonstrating the lipoprotein bands in the human serum, the electrophoresis was carried out in an agarose migration medium as described by R. I. Noble, I. Lipid Res. 9.693 (1968). A veronal buffer with a pH of 8.6 and with an ionic strength of 0.05 was used. After the electrophoresis had continued for an hour, the stencil was removed from the apparatus and put into a developing bath which consisted of 0.55 dextran-sulfate 2,000 and of a 2.2 aqueous calciumchloride solution. The carrier was allowed to stay in the bath for 15 to 20 minutes at room temperature. During that period a complete precipitation of the following lipoprotein bands occurred:
chylomicrons B-lipoproteins pre-[i-lipoproteins OZ-llPOPI'OIGlHS, which in FIG. 3a are denominated in turn with 1,2,3 and 4.
EXAMPLE 2 In accordance with example 1, type III human serum on an agar stencil was subjected to the electrophoresis in a veronal buffer having a pH of 8.6 and an ionic strength of 0.05 for the purpose of determining the hyperlipoproteinemia. After the electrophoresis had continued for an hour, the stencil was removed and put into a developing bath consisting of 0.25 heparin and 0.95 70 magnesium chloride in a 0.95 aqueous sodium-chloride solution and was allowed to stay in the bath for 20 minutes. The precipitation for the field VLDL, characteristic of type III was clearly to be recognised and is denominated with 5 in FIG. 3b. The field extends from the B-position 2 as far as the pre-B- position 3.
EXAMPLE 3 For demonstrating LPX-lipoprotein, four samples of human serum were inserted into the four holes of an object holder carrying an agar plate and by means of filter paper the object holder was connected with a veronal buffer solution, having a pH of 8.6 and an ionic strength of 0.05. The samples thus prepared were subjected to the electrophoresis. After the electrophoresis had continued for half an hour, the object holder was removed and put into a developing bath consisting of 0.25 heparin and 0.95 magnesium chloride in 0.9 aqueous sodium-chloride solution, and was allowed to stay in the bath for minutes. Two samples which are denoted with N in FIG. 3c were negative, in the other two positive samples, denoted with P, the LPX- band was easily recognisable and was denoted with 6.
EXAMPLE Human full plasm was subjected to a polyacrylamide-electrophoresis, according to the method by B. J. Davis, Ann. N.Y. Acad. Sci. 121, 404 (1964), wherein a tris-glycin buffer [tris-(hydroxymethyl)- aminomethane-buffer] with a pH of 8.8 and an acrylamide-monomer concentration of 3.5/7 was used. When the required separation effect had been achieved after a two-hour electrophoresis, the glass tube was removed from the apparatus, the polyacryl-amide gel was removed and treated with a developing solution of the following composition: 0.55 dextran sulfate 2,000 and 2.2 aqueous calcium-chloride solution.
The following lipoprotein bands were thus made visible and were identified:
pre-B-lipoproteins B-lipoproteins a-lipoproteins, which are denoted with 3,2 and 4 in FIG. 3d.
What we claim is:
1. A method of demonstrating normal and pathological plasm-lipoprotein patterns in human body liquids which comprises electrophoretically separating lipoproteins in a carrier medium or on foils,
upon occurrence of a desired electrophoretical separation effect, treating the carrier with a developing solution, comprising at least one of the following substances: polyanions, selected from the group consisting of heparin and dextran sulfate, sodiumdodcyl -sulfate (SOS), sodium phosphotung stic acid, sodium oleate, sodium salts of bile acids, lowsoluble complex salts being formed with the lipo- 1 proteins.
2. A method according to claim 1, wherein the carrier medium is a gel.
3. A method according to claim 1, wherein bivalent cations, selected from the group consisting of magnesium and calcium, are additionally present in the developing solution.
4. A method according to claim 1, wherein for demonstrating LP-X-lipoprotein, a developing solution is used which comprises heparin and magnesium ions.
5. A method according to claim 4, wherein the developing solution additionally contains sodium chloride.
6. A method according to claim 1, wherein for demonstrating lipoprotein type III a developing solution is used which comprises heparin and magnesium ions.
7. A method according to claim 6, wherein the developing solution additionally contains sodium chloride.
8. A method according toclaim 1, wherein for selectively demonstrating lipoprotein type III and lipoproteins VLDL, LDL and HDL the carrier is successively treated with a first developing solution and a second developing solution, the first developing solution comprising heparin and magnesium ions and the second developing solution comprising dextran sulfate and calcium ions.
9. A method according to claim 1, wherein for demonstrating lipoprotein LP-X a carrier is used which already contains at least parts of the developing solution.
10. A method according to claim 9, wherein the carrier is a gel plate.

Claims (10)

1. A METHOD OF DEMONSTRATING NORMAL AND PATHOLOGICAL PLASMA-LIPOPROTEIN PATTERNS IN HUMAN BODY LIQUIDS WHICH COMPRISES ELECTROPHORETICALLY SEPARATING LIPOPROTEINS IN A CARRIER MEDIUM OR ON FOILS, UPON OCCURRENCE OF A DESIRED ELECTROPHORETICAL SEPARATION EFFECT, TREATING THE CARRIER WITH A DEVELOPING SOLUTION, COMPRISING AT LEAST ONE OF THE FOLLOWING SUBSTANCES: POLYANIONS, SELECTED FROM THE GROUP CONSISTING OF HEPARIN AND DEXTRAN SULFATE, SODIUM-DODECYL-SULFATE (SOS), SODIUMPHOSPHOTUNGSTIC ACID, SODIUM OLEATE, SODIUM SALTS OF BILE
2. A method according to claim 1, wherein the carrier medium is a gel.
3. A method according to claim 1, wherein bivalent cations, selected from the group consisting of magnesium and calcium, are additionally present in the developing solution.
4. A method according to claim 1, wherein for demonstrating LP-X-lipoprotein, a developing solution is used which comprises heparin and magnesium ions.
5. A method according to claim 4, wherein the developing solution additionally contains sodium chloride.
6. A method according to claim 1, wherein for demonstrating lipoprotein type III a developing solution is used whiCh comprises heparin and magnesium ions.
7. A method according to claim 6, wherein the developing solution additionally contains sodium chloride.
8. A method according to claim 1, wherein for selectively demonstrating lipoprotein type III and lipoproteins VLDL, LDL and HDL the carrier is successively treated with a first developing solution and a second developing solution, the first developing solution comprising heparin and magnesium ions and the second developing solution comprising dextran sulfate and calcium ions.
9. A method according to claim 1, wherein for demonstrating lipoprotein LP-X a carrier is used which already contains at least parts of the developing solution.
10. A method according to claim 9, wherein the carrier is a gel plate.
US426202A 1973-02-12 1973-12-19 Method of demonstrating normal and pathological plasm-lipoprotein patterns in human body liquids Expired - Lifetime US3873433A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT121873A AT320865B (en) 1973-02-12 1973-02-12 Method for determining normal and pathological plasma lipoproteins in human body fluids and apparatus for carrying out the method

Publications (1)

Publication Number Publication Date
US3873433A true US3873433A (en) 1975-03-25

Family

ID=3509153

Family Applications (1)

Application Number Title Priority Date Filing Date
US426202A Expired - Lifetime US3873433A (en) 1973-02-12 1973-12-19 Method of demonstrating normal and pathological plasm-lipoprotein patterns in human body liquids

Country Status (10)

Country Link
US (1) US3873433A (en)
AT (1) AT320865B (en)
BE (1) BE810865A (en)
CH (1) CH598594A5 (en)
DE (1) DE2314964C3 (en)
FR (1) FR2217692B1 (en)
GB (1) GB1425545A (en)
NL (1) NL7317413A (en)
NO (1) NO146038C (en)
SE (1) SE408968B (en)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4105521A (en) * 1977-09-21 1978-08-08 Helena Laboratories Corporation Clinical procedure for measuring lipoprotein cholesterols
US4151065A (en) * 1978-01-30 1979-04-24 The Regents Of The University Of California Horizontal slab gel electrophoresis
US4167467A (en) * 1977-09-21 1979-09-11 Helena Laboratories Corporation Clinical procedure for measuring lipoprotein free cholesterols
US4234400A (en) * 1979-01-26 1980-11-18 The Regents Of The University Of California Horizontal slab gel electrophoresis
US4297198A (en) * 1978-05-29 1981-10-27 Mochihiko Ohashi Concentrating electrophoresis apparatus
US4298441A (en) * 1979-06-27 1981-11-03 Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte Method of preserving the electrophoretic properties of lipoproteins
US4306956A (en) * 1980-11-10 1981-12-22 Miles Laboratories, Inc. Discontinuous gel electrophoresis process
US4321120A (en) * 1980-03-19 1982-03-23 Nardi Ronald V Process for detecting proteins specific to hypertension in mammals
DE3234565A1 (en) * 1981-09-18 1983-05-05 Toa Medical Electronic Co., Ltd., Kobe, Hyogo SUPPORT BODY CELL IN AN ELECTROPHORETIC APPARATUS
US4405720A (en) * 1981-03-04 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services Silver stains for protein in gels
US4521519A (en) * 1981-05-02 1985-06-04 Boehringer Mannheim Gmbh Reagent for the precipitation of apo-B-containing lipoproteins
FR2560220A1 (en) * 1984-02-27 1985-08-30 Int Biotechnologies In HORIZONTAL GEL ELECTROPHORESIS DEVICE
US4709810A (en) * 1986-11-14 1987-12-01 Helena Laboratories Corporation Container for an electrophoretic support medium
US4782027A (en) * 1987-01-22 1988-11-01 President And Fellows Of Harvard College Protein detection by negative staining
US4911816A (en) * 1986-02-04 1990-03-27 Oncor, Inc. Process for conducting electrophoresis and transfer
US4954237A (en) * 1987-03-16 1990-09-04 Helena Laboratories Automatic electrophoresis apparatus
US5074981A (en) * 1989-04-26 1991-12-24 The University Of Tennessee Research Corporation High speed gel electrophoresis
US5168067A (en) * 1990-05-25 1992-12-01 Miller Michael A Method and kit for screening for apolipoprotein b or calculated ldl cholesterol
US5364793A (en) * 1990-11-30 1994-11-15 Monoclonetics International, Inc. Methods for the diagnosis of peripheral nerve damage
US5405520A (en) * 1994-01-27 1995-04-11 Eastman Kodak Company Connectors for electrophoresis device
US5844097A (en) * 1990-11-30 1998-12-01 Monoclonetics International, Inc. Methods for the diagnosis of peripheral nerve damage
US6063250A (en) * 1998-05-15 2000-05-16 C.C. Imex Running tank assembly for electrophoresis
WO2002037093A2 (en) * 2000-11-02 2002-05-10 Gene Bio-Application Ltd. Gel trap for electrophoresis
US6402915B1 (en) 1998-05-15 2002-06-11 C.C. Imex Running tank assembly for electrophoresis
WO2006082575A1 (en) * 2005-02-07 2006-08-10 Gene Bio-Application Ltd. Double chamber tank for horizontal gel electrophoresis
US20090071830A1 (en) * 2007-07-24 2009-03-19 Applied Biosystems Inc. Systems and Methods for Isolating Nucleic Acids

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK159837C (en) * 1986-12-03 1991-04-29 Radiometer As METHOD AND APPARATUS FOR DISCOVERING A PROTEIN POLLUTION ON A PH ELECTRODE

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3766047A (en) * 1972-09-11 1973-10-16 F Elevitch Gel for electrophoresis
US3773647A (en) * 1972-05-12 1973-11-20 Electro Nucleonics Low voltage electrophoretic testing system
US3783118A (en) * 1971-12-13 1974-01-01 Pharmacia Fine Chemicals Ab Method for the electrophoretic separation of substance mixtures

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3783118A (en) * 1971-12-13 1974-01-01 Pharmacia Fine Chemicals Ab Method for the electrophoretic separation of substance mixtures
US3773647A (en) * 1972-05-12 1973-11-20 Electro Nucleonics Low voltage electrophoretic testing system
US3766047A (en) * 1972-09-11 1973-10-16 F Elevitch Gel for electrophoresis

Cited By (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4147606A (en) * 1977-09-21 1979-04-03 Helena Laboratories Corporation Clinical procedure for measuring lipoprotein triglycerides
FR2404222A1 (en) * 1977-09-21 1979-04-20 Helena Lab Corp CLINICAL DETERMINATION PROCESS OF CHOLESTEROL LIPOPROTEINS
US4167467A (en) * 1977-09-21 1979-09-11 Helena Laboratories Corporation Clinical procedure for measuring lipoprotein free cholesterols
US4105521A (en) * 1977-09-21 1978-08-08 Helena Laboratories Corporation Clinical procedure for measuring lipoprotein cholesterols
US4151065A (en) * 1978-01-30 1979-04-24 The Regents Of The University Of California Horizontal slab gel electrophoresis
US4297198A (en) * 1978-05-29 1981-10-27 Mochihiko Ohashi Concentrating electrophoresis apparatus
US4234400A (en) * 1979-01-26 1980-11-18 The Regents Of The University Of California Horizontal slab gel electrophoresis
US4298441A (en) * 1979-06-27 1981-11-03 Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte Method of preserving the electrophoretic properties of lipoproteins
US4321120A (en) * 1980-03-19 1982-03-23 Nardi Ronald V Process for detecting proteins specific to hypertension in mammals
US4306956A (en) * 1980-11-10 1981-12-22 Miles Laboratories, Inc. Discontinuous gel electrophoresis process
US4405720A (en) * 1981-03-04 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services Silver stains for protein in gels
US4521519A (en) * 1981-05-02 1985-06-04 Boehringer Mannheim Gmbh Reagent for the precipitation of apo-B-containing lipoproteins
DE3234565A1 (en) * 1981-09-18 1983-05-05 Toa Medical Electronic Co., Ltd., Kobe, Hyogo SUPPORT BODY CELL IN AN ELECTROPHORETIC APPARATUS
US4414073A (en) * 1981-09-18 1983-11-08 Toa Medical Electronic Co., Ltd. Supporting body cell in electrophoretic apparatus
FR2560220A1 (en) * 1984-02-27 1985-08-30 Int Biotechnologies In HORIZONTAL GEL ELECTROPHORESIS DEVICE
US4588491A (en) * 1984-02-27 1986-05-13 International Biotechnologies, Inc. Horizontal gel electrophoresis device
US4911816A (en) * 1986-02-04 1990-03-27 Oncor, Inc. Process for conducting electrophoresis and transfer
US4709810A (en) * 1986-11-14 1987-12-01 Helena Laboratories Corporation Container for an electrophoretic support medium
US4782027A (en) * 1987-01-22 1988-11-01 President And Fellows Of Harvard College Protein detection by negative staining
US4954237A (en) * 1987-03-16 1990-09-04 Helena Laboratories Automatic electrophoresis apparatus
US5074981A (en) * 1989-04-26 1991-12-24 The University Of Tennessee Research Corporation High speed gel electrophoresis
US5168067A (en) * 1990-05-25 1992-12-01 Miller Michael A Method and kit for screening for apolipoprotein b or calculated ldl cholesterol
US5364793A (en) * 1990-11-30 1994-11-15 Monoclonetics International, Inc. Methods for the diagnosis of peripheral nerve damage
US5583201A (en) * 1990-11-30 1996-12-10 Monoclonetics International, Inc. Methods for diagnosis of peripheral nerve damage
US5844097A (en) * 1990-11-30 1998-12-01 Monoclonetics International, Inc. Methods for the diagnosis of peripheral nerve damage
US5405520A (en) * 1994-01-27 1995-04-11 Eastman Kodak Company Connectors for electrophoresis device
US6402915B1 (en) 1998-05-15 2002-06-11 C.C. Imex Running tank assembly for electrophoresis
US6063250A (en) * 1998-05-15 2000-05-16 C.C. Imex Running tank assembly for electrophoresis
WO2002037093A3 (en) * 2000-11-02 2002-07-25 Gene Bio Applic Ltd Gel trap for electrophoresis
WO2002037093A2 (en) * 2000-11-02 2002-05-10 Gene Bio-Application Ltd. Gel trap for electrophoresis
US20040020776A1 (en) * 2000-11-02 2004-02-05 Yitzhak Ben-Asouli Gel trap for electrophoresis
US20040020775A1 (en) * 2000-11-02 2004-02-05 Yitzhak Ben-Asouli Gel for electrophoresis
US20060207882A1 (en) * 2000-11-02 2006-09-21 Gene Bio-Application Ltd. Gel for electrophoresis
US7264703B2 (en) 2000-11-02 2007-09-04 Gene Bio-Application Ltd. Gel trap for electrophoresis
US7320747B2 (en) 2000-11-02 2008-01-22 Gene Bio-Application Ltd. Gel for electrophoresis
WO2006082575A1 (en) * 2005-02-07 2006-08-10 Gene Bio-Application Ltd. Double chamber tank for horizontal gel electrophoresis
US20080217178A1 (en) * 2005-02-07 2008-09-11 Yitzhak Ben-Asouli Double Chamber Tank for Horizontal Gel Electrophoresis
US8241477B2 (en) * 2005-02-07 2012-08-14 Gene Bio-Application Ltd. Double chamber tank for horizontal gel electrophoresis
US20090071830A1 (en) * 2007-07-24 2009-03-19 Applied Biosystems Inc. Systems and Methods for Isolating Nucleic Acids
US8568580B2 (en) * 2007-07-24 2013-10-29 Applied Biosystems, Llc Systems and methods for isolating nucleic acids

Also Published As

Publication number Publication date
NL7317413A (en) 1974-08-14
CH598594A5 (en) 1978-05-12
FR2217692B1 (en) 1978-02-17
DE2314964A1 (en) 1974-09-05
DE2314964B2 (en) 1975-03-27
AT320865B (en) 1975-03-10
FR2217692A1 (en) 1974-09-06
SE408968B (en) 1979-07-16
BE810865A (en) 1974-05-29
NO146038B (en) 1982-04-05
NO146038C (en) 1982-07-14
GB1425545A (en) 1976-02-18
DE2314964C3 (en) 1975-11-13

Similar Documents

Publication Publication Date Title
US3873433A (en) Method of demonstrating normal and pathological plasm-lipoprotein patterns in human body liquids
US3674678A (en) Electrophoretic apparatus
Seidel et al. Improved techniques for assessment of plasma lipoprotein patterns. I. Precipitation in gels after electrophoresis with polyanionic compounds
Frings et al. Electrophoretic separation of serum lipoproteins in polyacrylamide gel
US5078853A (en) Segmented electrophoretic separation system useful for lipid profiling
US4555490A (en) Rapid visualization system for gel electrophoresis
USRE24752E (en) Method of electrophoresis of serum proteins
AU662138B2 (en) Analysis of samples utilizing capillary electrophoresis
JP2003532894A (en) Electrophoretic separation of compounds
ES2198402T3 (en) PROCEDURE FOR SEPARATION OF THE LP (A) BY ELECTROPHORESIS AND APPLICATION IN THE IN VITRO DETERMINATION OF THE ATEROGENOUS RISK RELATED TO THE PRESENCE OF THE LP (A).
AU2003256261B2 (en) Method for pH-biased isoelectric trapping separations
Wieland et al. Improved techniques for assessment of serum lipoprotein patterns. II. Rapid method for diagnosis of type III hyperlipoproteinemia without ultracentrifugation
Skude et al. Thin layer electrofocusing followed by electrophoresis in antibody containing gel
US4824547A (en) Electrophoretic extraction of proteins from two-dimensional electrophoresis gel spots
Danno Isoelectric focusing of proteins separated by SDS-polyacrylamide gel electrophoresis
Bautovich et al. Gradient gel electrophoresis of human plasma lipoproteins
Hjertén Zone electrophoresis, isoelectric focusing, and displacement electrophoresis (isotachophoresis) in carrier-free solution
Merz et al. Segregation of membrane components using isoelectric focusing in polyacrylamide gels
Angellis et al. Isoelectric Focusing of Alkaline Phosphatase Isoenzymes in Polyacrylamide Gels: Use of Triton X-100 and Improved Staining Technic
US3826734A (en) Apparatus for use in liquid sample analysis
Vargas et al. Surface charge of endothelial cells estimated from electrophoretic mobility
ATE5749T1 (en) METHOD AND DIAGNOSTIC MEANS FOR DIRECT DETERMINATION OF BLOOD LIPID CONTENT OF BETALIPOPROTEINS.
Kinersly et al. Electrophoretic Study of Saliva
EP0034233A1 (en) Buffer composition, method for the electrophoretic separation of proteins and buffer solution therefor
Kiyoko et al. An ultramicro-assay for proteins in biological fluids other than blood using a combination of agarose gel isoelectric focusing and silver staining